Riou J F, Multon E, Vilarem M J, Larsen C J, Riou G
Biochem Biophys Res Commun. 1986 May 29;137(1):154-60. doi: 10.1016/0006-291x(86)91189-7.
Several antitumor drugs including DNA intercalative and non intercalative agents induce in vitro and in vivo double-stranded DNA breaks by stabilization of a topoisomerase II-DNA complex. In order to locate cleavage sites in an actively transcribed oncogene, N417 cells, originating from a human small cell lung carcinoma and containing 45-50 copies of c-myc oncogene, were treated with mAMSA, 9 hydroxyellipticine and VM 26. The presence of DNA lesions in c-myc was investigated by Southern blot hybridization with a human c-myc probe. In addition to normal bands, DNA patterns of drug treated-cells revealed the presence of new bands most likely corresponding to topoisomerase II-mediated cleavage as these bands were not found in untreated control DNA and in DNA treated with oAMSA, a biologically inactive stereoisomer of mAMSA. Major cleavage sites induced by drugs in the N417 cell c-myc locus were located in the 5' end of the c-myc exon 1 closely to some DNAse I hypersensitive sites which are assumed to reflect an activity of the gene. Therefore our data suggest that TopoII-mediated drug activity correlates with gene activity.
包括DNA嵌入剂和非嵌入剂在内的几种抗肿瘤药物通过稳定拓扑异构酶II-DNA复合物在体外和体内诱导双链DNA断裂。为了定位一个活跃转录的癌基因中的切割位点,用mAMSA、9-羟基椭圆玫瑰树碱和VM 26处理了源自人小细胞肺癌且含有45-50个c-myc癌基因拷贝的N417细胞。通过用人c-myc探针进行Southern印迹杂交研究c-myc中DNA损伤的存在情况。除了正常条带外,药物处理细胞的DNA图谱显示存在新条带,这些新条带很可能对应于拓扑异构酶II介导的切割,因为在未处理的对照DNA和用oAMSA(mAMSA的一种无生物学活性的立体异构体)处理的DNA中未发现这些条带。药物在N417细胞c-myc基因座中诱导的主要切割位点位于c-myc外显子1的5'端,靠近一些假定反映基因活性的DNA酶I超敏位点。因此,我们的数据表明拓扑异构酶II介导的药物活性与基因活性相关。